Low Dose IL-2 for the Treatment of Crohn's Disease
NCT04263831
This study is recruiting at 3 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to determine the safety and maximum effective dose (MED) of Interleukin-2 in subjects with moderate-to-severe crohn's disease.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Crohn Disease
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 12 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Boston Children's Hospital
- Last updated on ClinicalTrials.gov
- August 3, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Massachusetts · 2
- Boston Children's Hospital · Boston, MA
- Brigham and Women's Hospital · Boston, MA
New York · 1
- Mount Sinai · New York, NY
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.